Literature DB >> 17375011

[Necrotic livedo after injection of buprenorphine (Subutex)].

A Potier1, C Leclech, A Croue, D Chappard, J-L Verret.   

Abstract

INTRODUCTION: Use of buprenorphine (Subutex) is widely used as substitution treatment in opiate addiction although its side-effects are little known. We report a case of localised necrotic livedo subsequent to injection of Subutex. OBSERVATION: A 34 year-old male drug addict on Subutex substitution treatment presented a necrotic livedo and an ulcer with clearly demarcated edges on the skin of the inner elbow. Histological analysis revealed PAS-positive particles in a hypodermic inflammatory lymphohistiocytic infiltrate that were reflective and formed a Maltese cross under polarised light and were identified as maize starch. DISCUSSION: This clinical case describes necrotic livedo lesions induced by injection of Subutex. The underlying mechanisms are associated with maize starch, an excipient used in Subutex. Unauthorised subcutaneous injection of buprenorphine (Subutex) is common among drug addicts but there is little description of the associated complications. In our patient, the presence in cutaneous biopsy samples of maize starch, an excipient of buprenorphine, provides evidence of intravenous administration of this drug.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17375011     DOI: 10.1016/s0151-9638(07)91607-5

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  2 in total

1.  Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions.

Authors:  Régis Bouquié; Laura Wainstein; Paul Pilet; Jean-Marie Mussini; Guillaume Deslandes; Johann Clouet; Eric Dailly; Pascale Jolliet; Caroline Victorri-Vigneau
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

2.  Livedoid Dermatitis Treated With Nifedipine.

Authors:  Lee Wheless; Lilly Zhu; Mona Mashayekhi; Rachel B Fissell
Journal:  J Investig Med High Impact Case Rep       Date:  2016-02-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.